<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sadasivam P</submitter><funding>NIBIB NIH HHS</funding><funding>NCATS NIH HHS</funding><funding>NIA NIH HHS</funding><funding>National Institute of Biomedical Imaging and Bioengineering</funding><funding>National Institute on Aging</funding><pagination>372-381</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8105262</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>23(3)</volume><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Synapse loss is a hallmark of Alzheimer's disease (AD) and correlates with cognitive decline. The validation of a noninvasive in vivo imaging approach to quantify synapse would greatly facilitate our understanding of AD pathogenesis and assist drug developments for AD. As animal models of neurodegenerative and neuropsychiatric disorders play a critical role in the drug discovery and development process, a robust, objective, and translational method for quantifying therapeutic drug efficacy in animal models will facilitate the drug development process. In this study, we tested the quantification reliability of the SV2A PET tracer, [&lt;sup>18&lt;/sup>F]SynVesT-1, in a mouse model of AD (APP/PS1) and wild-type controls, and developed a simplified quantification method to facilitate</pubmed_abstract><journal>Molecular imaging and biology</journal><pubmed_title>Quantification of SV2A Binding in Rodent Brain Using [&lt;sup>18&lt;/sup>F]SynVesT-1 and PET Imaging.</pubmed_title><pmcid>PMC8105262</pmcid><funding_grant_id>K01EB023312</funding_grant_id><funding_grant_id>K01 EB023312</funding_grant_id><funding_grant_id>R01 AG052560</funding_grant_id><funding_grant_id>R01 AG034924</funding_grant_id><funding_grant_id>R01 AG058773</funding_grant_id><funding_grant_id>R01AG052560</funding_grant_id><funding_grant_id>UL1 TR001863</funding_grant_id><funding_grant_id>R01AG058773</funding_grant_id><funding_grant_id>P30 AG066508</funding_grant_id><pubmed_authors>Toyonaga T</pubmed_authors><pubmed_authors>Lee S</pubmed_authors><pubmed_authors>Huang Y</pubmed_authors><pubmed_authors>Spurrier J</pubmed_authors><pubmed_authors>Carson RE</pubmed_authors><pubmed_authors>Cai Z</pubmed_authors><pubmed_authors>Sadasivam P</pubmed_authors><pubmed_authors>Zheng MQ</pubmed_authors><pubmed_authors>Fang XT</pubmed_authors><pubmed_authors>Xu Y</pubmed_authors><pubmed_authors>Strittmatter SM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Quantification of SV2A Binding in Rodent Brain Using [&lt;sup>18&lt;/sup>F]SynVesT-1 and PET Imaging.</name><description>&lt;h4>Purpose&lt;/h4>Synapse loss is a hallmark of Alzheimer's disease (AD) and correlates with cognitive decline. The validation of a noninvasive in vivo imaging approach to quantify synapse would greatly facilitate our understanding of AD pathogenesis and assist drug developments for AD. As animal models of neurodegenerative and neuropsychiatric disorders play a critical role in the drug discovery and development process, a robust, objective, and translational method for quantifying therapeutic drug efficacy in animal models will facilitate the drug development process. In this study, we tested the quantification reliability of the SV2A PET tracer, [&lt;sup>18&lt;/sup>F]SynVesT-1, in a mouse model of AD (APP/PS1) and wild-type controls, and developed a simplified quantification method to facilitate</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jun</publication><modification>2025-04-29T11:30:10.772Z</modification><creation>2025-04-06T19:54:38.031Z</creation></dates><accession>S-EPMC8105262</accession><cross_references><pubmed>33258040</pubmed><doi>10.1007/s11307-020-01567-9</doi></cross_references></HashMap>